Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Gingko Bioworks' lab facility. Photo: Gingko Bioworks
Ginkgo Bioworks is in the business of designing and printing microbes, but it recently raised $275 million — bringing its valuation to over $1 billion — because it sees itself more akin to a software company.
Why it matters: The Boston-based company says that, by providing specialized services for designing, developing, and printing DNA, it can open possibilities for customers in industries outside of health care.
For example, a fragrance company can pay Ginkgo Bioworks for a project that would otherwise be too expensive to do in-house, according to co-founder and CEO Jason Kelly. A pharma company would have to hire scientists to do the development itself.
Deal details: Investors in the round include Viking Global, Y Combinator's Continuity Fund, Cascade Investment (Bill Gates' investment vehicle), and General Atlantic. Though Kelly declined to specify the new valuation, a Delaware filing first spotted by Recode pegs it at $1.3 billion.
Part of the proceeds will be used to open a third lab facility.